BRAF and adenocarcinoma: Adenocarcinomas frequently harbor mutations in EGFR, KRAS, B-Raf proto-oncogene (BRAF), and rearrangements involving ALK, c-ros oncogene 1 (ROS1), and rearranged during transfection (RET), which serve as critical predictive biomarkers and therapeutic targets [15,16].